{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T09:48:35Z","timestamp":1785836915451,"version":"3.56.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,4]]},"DOI":"10.7759\/cureus.113927","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T09:40:08Z","timestamp":1785836408000},"source":"Crossref","is-referenced-by-count":0,"title":["Daraxonrasib: A Breakthrough in Pancreatic Ductal Adenocarcinoma"],"prefix":"10.7759","author":[{"given":"George S","family":"Zacharia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udesh","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ornela","family":"Thartori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FNU","family":"Veena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samrachana","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lav","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyansh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harish","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"American Cancer Society. Key statistics for pancreatic cancer. (2026). Accessed. June 18, 2026: https:\/\/www.cancer.org\/cancer\/types\/pancreatic-cancer\/about\/key-statistics.html."},{"key":"ref2","unstructured":"American Cancer Society. Survival rates for pancreatic cancer. (2026). Accessed. June 18, 2026: https:\/\/www.cancer.org\/cancer\/types\/pancreatic-cancer\/detection-diagnosis-staging\/survival-rates.html."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1172\/JCI191370","article-title":"Oncogenic KRAS\/ERK\/JUNB signaling suppresses differentiation regulator GATA6 in pancreatic cancer","volume":"136","author":"Zhong Z","year":"2026","unstructured":"Zhong Z, Cao X, Liao PJ, et al.. Oncogenic KRAS\/ERK\/JUNB signaling suppresses differentiation regulator GATA6 in pancreatic cancer. J Clin Invest. 2026, 136:10.1172\/JCI191370","journal-title":"J Clin Invest"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c02314","article-title":"Discovery of daraxonrasib (RMC-6236), a potent and orally bioavailable RAS(ON) multi-selective, noncovalent tri-complex inhibitor for the treatment of patients with multiple RAS-addicted cancers","volume":"68","author":"Cregg J","year":"2025","unstructured":"Cregg J, Edwards AV, Chang S, et al.. Discovery of daraxonrasib (RMC-6236), a potent and orally bioavailable RAS(ON) multi-selective, noncovalent tri-complex inhibitor for the treatment of patients with multiple RAS-addicted cancers. J Med Chem. 2025, 68:6064-83. 10.1021\/acs.jmedchem.4c02314","journal-title":"J Med Chem"},{"key":"ref5","unstructured":"FDA permits expanded access for investigational pancreatic cancer drug. (2026). Accessed. June 18, 2026: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-permits-expanded-access-investigational-pancreatic-cancer-drug."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1172\/JCI191937","article-title":"Early neoplastic lesions of the pancreas: initiation, progression, and opportunities for precancer interception","volume":"135","author":"Pedro BA","year":"2025","unstructured":"Pedro BA, Wood LD. Early neoplastic lesions of the pancreas: initiation, progression, and opportunities for precancer interception. J Clin Invest. 2025, 135:10.1172\/JCI191937","journal-title":"J Clin Invest"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-1545","article-title":"Can we predict the progression of premalignant pancreatic cystic tumors to ductal adenocarcinoma?","volume":"18","author":"Chidambaram S","year":"2022","unstructured":"Chidambaram S, Kawka M, Gall TM, Cunningham D, Jiao LR. Can we predict the progression of premalignant pancreatic cystic tumors to ductal adenocarcinoma?. Future Oncol. 2022, 18:2605-12. 10.2217\/fon-2021-1545","journal-title":"Future Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000533","article-title":"A revised classification system and recommendations from the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas","volume":"39","author":"Basturk O","year":"2015","unstructured":"Basturk O, Hong SM, Wood LD, et al.. A revised classification system and recommendations from the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas. Am J Surg Pathol. 2015, 39:1730-41. 10.1097\/PAS.0000000000000533","journal-title":"Am J Surg Pathol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.21037\/cco-22-4","article-title":"Genetic landscape of pancreatic cancer: a narrative review","volume":"11","author":"Yakar D\u00d6","year":"2022","unstructured":"Yakar D\u00d6, Bozk\u0131rl\u0131 BO, Ceyhan GO. Genetic landscape of pancreatic cancer: a narrative review. Chin Clin Oncol. 2022, 11:5. 10.21037\/cco-22-4","journal-title":"Chin Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00659-4","article-title":"The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives","volume":"6","author":"Wang S","year":"2021","unstructured":"Wang S, Zheng Y, Yang F, et al.. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Signal Transduct Target Ther. 2021, 6:249. 10.1038\/s41392-021-00659-4","journal-title":"Signal Transduct Target Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01087-1","article-title":"Molecular characterization and prognostic implications of KRAS mutations in pancreatic cancer patients: insights from multi-cohort analysis","volume":"9","author":"Jiang Y","year":"2025","unstructured":"Jiang Y, Mai G, Zhao X, et al.. Molecular characterization and prognostic implications of KRAS mutations in pancreatic cancer patients: insights from multi-cohort analysis. NPJ Precis Oncol. 2025, 9:299. 10.1038\/s41698-025-01087-1","journal-title":"NPJ Precis Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1147676","article-title":"KRAS mutation: the booster of pancreatic ductal adenocarcinoma transformation and progression","volume":"11","author":"Zhang Z","year":"2023","unstructured":"Zhang Z, Zhang H, Liao X, Tsai HI. KRAS mutation: the booster of pancreatic ductal adenocarcinoma transformation and progression. Front Cell Dev Biol. 2023, 11:1147676. 10.3389\/fcell.2023.1147676","journal-title":"Front Cell Dev Biol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-25-1519","article-title":"Correction: translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers","volume":"15","author":"Jiang J","year":"2025","unstructured":"Jiang J, Jiang L, Maldonato BJ, et al.. Correction: translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers. Cancer Discov. 2025, 15:2186. 10.1158\/2159-8290.CD-25-1519","journal-title":"Cancer Discov"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505783","article-title":"Daraxonrasib in previously treated advanced RAS-mutated pancreatic cancer","volume":"394","author":"Wolpin BM","year":"2026","unstructured":"Wolpin BM, Park W, Garrido-Laguna I, et al.. Daraxonrasib in previously treated advanced RAS-mutated pancreatic cancer. N Engl J Med. 2026, 394:1790-802. 10.1056\/NEJMoa2505783","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2026.108226","article-title":"Daraxonrasib (RMC-6236) pharmacokinetics: impact of transporters and drug-metabolizing enzymes on a first-in-class pan-RAS molecular glue","volume":"229","author":"Arguedas D","year":"2026","unstructured":"Arguedas D, Bui V, Law T, et al.. Daraxonrasib (RMC-6236) pharmacokinetics: impact of transporters and drug-metabolizing enzymes on a first-in-class pan-RAS molecular glue. Pharmacol Res. 2026, 229:108226. 10.1016\/j.phrs.2026.108226","journal-title":"Pharmacol Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2610708123","article-title":"A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance","volume":"123","author":"Liaki V","year":"2026","unstructured":"Liaki V, Barrambana S, Kostopoulou M, et al.. A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance. Proc Natl Acad Sci U S A. 2026, 123:e2610708123. 10.1073\/pnas.2610708123","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.64898\/2025.12.06.692635","article-title":"PCNA inhibition enhances the antitumor activity of KRAS-targeted therapies in pancreatic cancer","author":"Bannoura SF","year":"2025","unstructured":"Bannoura SF, Khan HY, Aboukameel A, et al.. PCNA inhibition enhances the antitumor activity of KRAS-targeted therapies in pancreatic cancer. bioRxiv. 2025, 10.64898\/2025.12.06.692635","journal-title":"bioRxiv"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-1475","article-title":"T-cell dependency of tumor regressions and complete responses with RAS(ON) multi-selective inhibition in preclinical models of pancreatic ductal adenocarcinoma","volume":"15","author":"Orlen M","year":"2025","unstructured":"Orlen M, Vostrejs WP, Sor R, et al.. T-cell dependency of tumor regressions and complete responses with RAS(ON) multi-selective inhibition in preclinical models of pancreatic ductal adenocarcinoma. Cancer Discov. 2025, 15:1697-716. 10.1158\/2159-8290.CD-24-1475","journal-title":"Cancer Discov"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2605555","article-title":"Daraxonrasib or chemotherapy in previously treated metastatic Pancreatic Cancer","volume":"395","author":"O'Reilly EM","year":"2026","unstructured":"O'Reilly EM, Wainberg ZA, Hendifar AE, et al.. Daraxonrasib or chemotherapy in previously treated metastatic Pancreatic Cancer. N Engl J Med. 2026, 395:325-37. 10.1056\/NEJMoa2605555","journal-title":"N Engl J Med"},{"key":"ref20","unstructured":"ClinicalTrials.gov. Study of daraxonrasib and daraxonrasib + GnP as first-line treatment in patients with metastatic pancreatic adenocarcinoma (RASolute 303). (2026). Accessed. June 18, 2026: https:\/\/clinicaltrials.gov\/study\/NCT07491445."},{"key":"ref21","unstructured":"GlobalData Healthcare. ASCO26. RevMed's daraxonrasib presents a turning point for pancreatic cancer. (2026). Accessed: June 18, 2026: https:\/\/www.pharmaceutical-technology.com\/analyst-comment\/asco26-revmeds-daraxonrasib-presents-a-turning-point-for-pa...."},{"key":"ref22","unstructured":"Study of daraxonrasib (RMC-6236) in patients with resected pancreatic ductal adenocarcinoma (PDAC) (RASolute 304). (2026). Accessed. July 25, 2026: https:\/\/clinicaltrials.gov\/study\/NCT07252232."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/509930-daraxonrasib-a-breakthrough-in-pancreatic-ductal-adenocarcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T09:40:11Z","timestamp":1785836411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/509930-daraxonrasib-a-breakthrough-in-pancreatic-ductal-adenocarcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.113927","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,4]]}}}